Evaluation of the effects of ultra-long acting insulin analogue on diabetic vascular complication

Evaluation of the effects of ultra-long acting insulin analogue on diabetic vascular complication - EVOLUTION

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004973

Enrollment

Registered

2011-03-30

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes

Interventions

First, detemir treatment for 6 months, and then glargin treatment for 6 months First, glargin treatment for 6 months, and then detemir treatment for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients whose HbA1c level over 7%

Exclusion criteria

Exclusion criteria: Patients modified ACEI/ARB, statin, pioglitzone therapy within 1 months Patients with pregnancy

Design outcomes

Primary

Measure	Time frame
Flow mediated vasodilatation	—

Secondary

Measure	Time frame
urinary albumin excretion, Vascular endothelial growth factor, Plasminogen activator inhibitor-1, , Adiponectin, Leptin, Ghrelin, high sensitive CRP	—

Countries

Japan

Contacts

Public ContactHisashi Makino

National Cerebral Cardiovascular Center Endocrinology and Metabolism

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026